Marketing copy for CBD oil tends to outrun the science behind it, but that doesn’t mean the science is empty. A handful of peer-reviewed studies specifically involving dogs exist, and they’re worth walking through directly rather than taking secondhand summaries at face value.
Cornell University’s College of Veterinary Medicine ran a study published in 2018 looking at CBD’s effect on dogs diagnosed with osteoarthritis. Using a dose of 2 mg/kg administered twice daily over an eight-week period, researchers measured outcomes using the Canine Brief Pain Inventory, a validated tool vets use to assess pain severity and its interference with daily activity. Dogs receiving CBD showed a decrease in pain scores and an increase in activity level compared to the placebo group. No significant adverse effects were reported at that particular dosage during the trial window. The study used a randomized, placebo-controlled, double-blinded crossover design, which is generally considered a stronger methodology than an open-label trial where both owner and researcher know which dogs are receiving the actual compound.
Colorado State University published research in the Journal of the American Veterinary Medical Association examining CBD’s effect on canine epilepsy. Dogs already on standard anti-seizure medication who additionally received CBD oil showed reduced seizure frequency compared to those on placebo. The study involved only 16 dogs, a sample size small enough that the authors themselves called for larger follow-up research before drawing firm conclusions. Interestingly, the study also found that dogs with higher CBD blood levels showed a greater reduction in seizure frequency, suggesting a possible dose-response relationship worth exploring further in larger trials.
Here’s a fact that gets left out of most marketing summaries: a later Cornell study looking at CBD in dogs with both osteoarthritis and epilepsy found elevated liver enzyme levels in some dogs receiving higher doses. That’s not a reason to dismiss Holistapet CBD oil for dogs outright, but it is a reason dosage and, in some cases, periodic bloodwork matter more than a “just give more if it’s not working” approach.
Smaller Studies and What They Add
Beyond the two flagship studies most commonly cited, smaller pharmacokinetic studies have looked at how quickly CBD is absorbed and cleared from a dog’s system depending on the delivery method. These studies generally find that CBD oil taken orally has lower bioavailability in dogs compared to injection (unsurprising, since injection bypasses digestion entirely), and that dogs seem to clear CBD from their system somewhat differently than humans do, which is part of why dosing guidance developed for human use doesn’t translate directly to canine use. This is a technical point, but it matters: a milligram-per-kilogram dose that works for a human isn’t automatically the right starting point for a dog of the same relative body weight.
Reading Past the Headline Claims
A few specific gaps remain in the current body of research:
- Long-term safety data beyond several months of continuous use is limited
- Dosing standards differ by condition, and no single milligram-per-kilogram number applies universally
- Interaction risk with common medications, particularly those metabolized through the liver, isn’t fully mapped
- Individual variation in response between dogs, even within the same breed and weight class, is significant and not yet well explained
- Most published studies have focused on middle-aged to senior dogs with existing conditions rather than healthy dogs using CBD preventatively, so evidence for general wellness use is thinner than evidence for condition-specific use
A Simple Table of What’s Been Studied
| Condition | Studied At | Study Size | General Finding |
|---|---|---|---|
| Osteoarthritis pain | Cornell University | Small clinical trial | Reduced pain scores, increased activity |
| Epilepsy/seizures | Colorado State University | 16 dogs | Reduced seizure frequency vs. placebo |
| Combined conditions | Cornell University (follow-up) | Small clinical trial | Elevated liver enzymes in some higher-dose subjects |
Small sample sizes are the recurring theme across this research. That’s not a knock against the researchers, it reflects how expensive and logistically difficult veterinary clinical trials are to run at scale. It does mean owners should treat “clinically studied” marketing claims with some skepticism unless the specific study, sample size, and journal are named.
Borrowing From Human Research, Cautiously
CBD research in humans is considerably further along, and the FDA has approved one CBD-based drug, Epidiolex, for treating specific severe forms of epilepsy in humans. That approval is sometimes cited in pet marketing as evidence of CBD’s general safety and effectiveness, which stretches the point further than it should. Epidiolex is a highly purified, pharmaceutical-grade CBD isolate, dosed and monitored under strict clinical protocol, and its approval was specific to particular human seizure conditions after extensive human trials. It doesn’t directly translate into an approval or even a strong evidentiary basis for a general-purpose pet supplement, though the underlying interest in CBD as a seizure-related compound is part of what motivated the Colorado State University canine study in the first place.
Placebo Effect and Owner Observation Bias
Worth flagging directly: much of the enthusiasm around CBD oil for dogs comes from owner-reported improvement rather than veterinarian-measured clinical outcomes. Owners want their dog to feel better, and that desire can shape how a subtle behavioral change gets interpreted, a well-documented phenomenon in human medicine known as observer or placebo-adjacent bias, which is part of why the Cornell and Colorado State studies used blinded, placebo-controlled designs rather than relying purely on owner testimonial. This isn’t a dismissal of the positive findings in those specific trials, since the blinding specifically guards against this bias, but it is a reason to weigh informal online reviews and testimonials less heavily than the actual published, controlled research.
Why the FDA Hasn’t Moved Faster
Drug approval requires a level of evidence these early studies haven’t yet reached: larger sample sizes, longer observation periods, and replication across multiple research institutions. Until that evidence base grows, CBD oil will likely continue existing in its current supplement classification rather than moving toward a formally approved veterinary drug status. Funding is part of the holdup too. Veterinary clinical trials of this scale are expensive, and without a pharmaceutical company pursuing formal drug approval (which would justify the cost through eventual sales of an approved product), much of the current research relies on university grants and smaller-scale funding that limits how large a trial can practically get.
Regulatory approval pathways for animal drugs also differ somewhat from the human drug pathway, running through the FDA’s Center for Veterinary Medicine rather than the same center that reviewed Epidiolex for human use. That center has its own evidentiary requirements and its own timeline, and as of now it hasn’t approved a CBD-based product through that specific pathway either, which is a separate fact from the general FDA supplement classification CBD oil currently falls under.
What a Pet Owner Can Reasonably Take From This
None of this means the existing research should be dismissed. Two separate university studies, using randomized, placebo-controlled designs, found measurable benefit for two specific conditions. That’s a meaningfully stronger evidence base than most pet supplements on the market can claim, even if it falls short of the evidence bar required for formal drug approval. The honest takeaway sits between the extremes of “completely unproven” and “clinically established,” closer to “promising for specific, studied uses, with real gaps still remaining.”
Breed and Size Variation
None of the major published trials have been large enough to break results down meaningfully by breed, which leaves an open question about whether, say, a Chihuahua and a Great Dane metabolize CBD at comparable relative rates once body weight is accounted for. Veterinary pharmacology more broadly recognizes that metabolic rate doesn’t always scale in a perfectly linear way with body weight across very different size classes, which is part of why some clinicians who work with CBD suggest starting more conservatively with both very small and very large breeds until more size-specific data becomes available. This is professional caution rather than a documented finding, worth noting as a distinction.
Where Research Seems to Be Headed Next
Ongoing interest from veterinary schools suggests the research base will likely keep growing, particularly around dosing standardization and longer observation windows past the eight-to-twelve week mark most current studies have used. Larger multi-site trials, ones pooling data across several veterinary schools rather than relying on a single institution’s patient population, would help address the small sample size problem that limits how confidently current findings can be generalized. Until that happens, the existing Cornell and Colorado State studies remain the two most frequently cited reference points in this specific area.
Peer review itself is worth a quick word here too. Both flagship studies went through the standard peer review process required for publication in the Journal of the American Veterinary Medical Association and comparable outlets, meaning independent experts in the field evaluated the methodology before publication. That’s a meaningfully different bar than a company-funded white paper or an in-house study that never went through outside review, and it’s a distinction worth checking whenever a product’s marketing cites “research” without naming where or how that research was published.
Final Thoughts
The existing peer-reviewed research on CBD oil in dogs shows real, cautiously positive results for osteoarthritis pain and seizure frequency specifically, but sample sizes remain small and questions about long-term safety and standardized dosing are still open.
